Browse the corpus

Finasteride, an FDA-approved therapeutic agent, plays a pivotal role in managing benign prostate hyperplasia and androgenic alopecia (male pattern hair loss) in men. Through its competitive inhibition of 5-alpha-reductase (types II and III isoenzymes), finasteride impedes the conversion of testosterone to dihydrotestosterone (DHT), addressing the underlying pathophysiology of these conditions. This activity discusses finasteride's diverse applications, extending beyond its primary indications to treat hyperandrogenism-associated manifestations, such as hirsutism. Additionally, the module explores the potential utilization of finasteride in transgender women, particularly when combined with estrogen, harnessing its anti-androgenic properties. The program outlines the recommended dosing, highlights significant adverse effects, identifies contraindications, and elucidates the essential aspects of monitoring and managing potential toxicity. By imparting an understanding of finasteride's mechanisms and clinical applications, this activity empowers healthcare providers to navigate patient therapy effectively, guiding them toward optimal outcomes. Objectives: Select appropriate patients for finasteride therapy, considering age, medical history, and treatment preferences. Differentiate between the therapeutic uses and dosing regimens of finasteride for BPH and male pattern hair loss. Screen patients for contraindications and potential drug interactions before initiating finasteride therapy. Implement follow-up care and patient monitoring on long-term finasteride therapy to ensure treatment efficacy and safety. Access free multiple choice questions on this topic.

Single doses up to 400 mg and multiple dosages up to 80 mg daily for 3 months are well-tolerated and have not resulted in significant adverse reactions in clinical studies. Until further data is obtained, no specific treatment for an overdose of finasteride can be recommended. There are no reports of overdoses of finasteride resulting in clinically significant toxicity. However, overdoses could be an extension of previously reported adverse drug effects, including orthostatic hypotension. According to the CDC, finasteride is included in the National Institute for Occupational Safety and Health (NIOSH) list of hazardous agents. Use proper precautions during handling and prescribing, and monitor patients appropriately.

Finasteride is an FDA-approved pharmacologic agent for treating benign prostate hyperplasia and androgenic alopecia (male pattern hair loss) in men. Urologists and dermatologists commonly prescribe finasteride for BPH and androgenic alopecia, respectively. The drug is also sometimes used to treat hyperandrogenism and hirsutism. All patients should receive risk versus benefit information, including the risk of high-grade prostate cancer. Female patients of childbearing potential should be informed about the possibility of the medication causing harm to the fetus and the importance of contraception while using the drug. Nurses should verify the dose for appropriate indications and ensure the patient understands the use of finasteride. Pharmacists should perform medication reconciliation, check for potential drug interactions, counsel patients, and report any concerns to the prescriber. This requires nurses and pharmacists to communicate openly with clinicians and be empowered to voice any concerns regarding issues they note in the patient's case. This is true in all instances, especially when the drug is used off-label in females for hirsutism. For example, if a nurse determines a female patient is not exercising proper birth control while on finasteride, they should immediately report the need for remedial action to the prescriber.